Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • Cabrera, S.
  • de la Calle, Irene|||0000-0002-2227-1640
  • Baulies Caballero, Sonia|||0000-0001-7670-5603
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer, towards the clinical application

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Arias, Efigenia
  • Sampayo, Victoria
  • Diaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández Gutierrez, Alicia|||0000-0002-2494-3041
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes. The online version contains supplementary material available at 10.1186/s13046-024-03158-w.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

  • Sanegre, Sabina
  • Eritja, Núria
  • Andrea, Carlos de
  • Díaz-Martín, Juan
  • Díaz-Lagares, Ángel
  • Jácome, M. A.
  • Salguero Aranda, Carmen
  • García-Ros, David
  • Davidson, Ben
  • López-López, Rafael
  • Melero, Ignacio
  • Navarro, Samuel
  • Ramón y Cajal, Santiago
  • Alava, Enrique de
  • Matias-Guiu, Xavier
  • Noguera, Rosa
[Abstract] The invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular matrix and secreted factors ultimately determine the fate of the tumor. Herein we focus on the invasive tumor front, making an in-depth characterization of reticular fiber scaffolding, infiltrating immune cells, gene expression, and epigenetic profiles of classified aggressive primary uterine adenocarcinomas (24 patients) and leiomyosarcomas (11 patients). Sections of formalin-fixed samples before and after microdissection were scanned and studied. Reticular fiber architecture and immune cell infiltration were analyzed by automatized algorithms in colocalized regions of interest. Despite morphometric resemblance between reticular fibers and high presence of macrophages, we found some variance in other immune cell populations and distinctive gene expression and cell adhesion-related methylation signatures. Although no evident overall differences in immune response were detected at the gene expression and methylation level, impaired antimicrobial humoral response might be involved in uterine leiomyosarcoma spread. Similarities found at the invasive tumor front of uterine adenocarcinomas and leiomyosarcomas could facilitate the use of common biomarkers and therapies. Furthermore, molecular and architectural characterization of the invasive front of uterine malignancies may provide additional prognostic information beyond established prognostic factors., This research was supported by grants from the ISCIII and ERDF (PI17/01558 and PI20/01107), by the CIBERONC (contracts CB16/12/00484, CB16/12/0328, CB16/12/00363, CB16/12/00364, CB16/12/00481, and CB16/12/00231) and Grupos Coordinados Estables from the Asociación Española Contra el Cáncer (AECC). ÁD-L was funded by a contract “Juan Rodés” from the ISCIII (JR17/00016).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • De la Calle Fuentes, Irene
  • Baulies, Sonia
  • Cabrera, Silvia
  • Gil-Moreno, Antonio
  • Colás Ortega, Eva
Diagnosis; Endometrial cancer; Screening, Diagnòstic; Càncer d'endometri; Cribratge, Diagnóstico; Cáncer de endometrio; Cribado, Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies., This research was funded by: Instituto de Salud Carlos III (ISCIII) grant number PI20/00644, PI23/01470, IFI19/00029 to E.C.R., IFI22/00019 to I.C., and CP22/00147 to E.C.; Grant number AC21_2/00030; Ministerio de Ciencia, Innovación y Universidades through a Proyectos en Colaboración Publico-Privada 2021 grant number CPP2022-009817, co-financed by the European Regional Development Fund (FEDER); Generalitat de Catalunya: SGR 2021 01157; CIBERONC network grant number CB16/12/00328; European Comission by Era PerMed project financed by AECC (grant number PERME212443COLA).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta
  • Gatius, Sònia
  • Bonnin, Sarah
  • Ruiz-Miró, Maria
  • González, Esperanza
  • Gil Moreno, Antonio
  • Colas Ortega, Eva
  • Moiola, Cristian Pablo
Taqman OpenArray technology; Lung cancer diagnosis; Biomarkers, Tecnología Taqman OpenArray; Diagnóstico de cáncer de pulmón; Biomarcadores, Tecnologia Taqman OpenArray; Diagnòstic del càncer de pulmó; Biomarcadors, Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis., The sample collection was supported by IRBLleida BIOBANK (B.0000682) and Plataforma biobancos PT17/0015/0027.EC hold a postdoctoral fellowship from the Departament de Salut of the Generalitat de Catalunya (SLT002/16/00274). This study was supported by: “Discovery, validation and implementation of biomarkers for Precision Oncology” (ISCIII PIE15/00029), CIBERONC (CB16/12/00231 and CB16/12/00328), Grups consolidats de la Generalitat de Catalunya (2017SGR1368 and 2017SGR1661) and Asociación Española contra el Cancer (GCTRA1804MATI).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Diaz, Eva
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Alonso-Alconada, Lorena
  • Ferreiros, Alba
  • Abalo, Alicia
  • López Gil, Carlos
  • Oltra, Sara S.
  • de Santiago, Javier
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Sampayo, Victoria
  • Bouso, Marta
  • Arias, Efigenia
  • Cueva, Juan|||0000-0003-1389-4595
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Vilar, Ana
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
The incidence and mortality of endometrial cancer (EC) have risen in recent years, hence more precise management is needed. Therefore, we combined different types of liquid biopsies to better characterize the genetic landscape of EC in a non-invasive and dynamic manner. Uterine aspirates (UAs) from 60 patients with EC were obtained during surgery and analyzed by next-generation sequencing (NGS). Blood samples, collected at surgery, were used for cell-free DNA (cfDNA) and circulating tumor cell (CTC) analyses. Finally, personalized therapies were tested in patient-derived xenografts (PDXs) generated from the UAs. NGS analyses revealed the presence of genetic alterations in 93% of the tumors. Circulating tumor DNA (ctDNA) was present in 41.2% of cases, mainly in patients with high-risk tumors, thus indicating a clear association with a more aggressive disease. Accordingly, the results obtained during the post-surgery follow-up indicated the presence of ctDNA in three patients with progressive disease. Moreover, 38.9% of patients were positive for CTCs at surgery. Finally, the efficacy of targeted therapies based on the UA-specific mutational landscape was demonstrated in PDX models. Our study indicates the potential clinical applicability of a personalized strategy based on a combination of different liquid biopsies to characterize and monitor tumor evolution, and to identify targeted therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer

  • Parrilla, Alfonso
  • Barber, Marta
  • Majem Cavaller, Blanca|||0000-0003-3613-0432
  • Castellvi, Josep|||0000-0001-5745-9996
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Sánchez Iglesias, José Luis|||0000-0002-4542-3969
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic protein that plays a key role in activating the master mitotic kinase polo-like kinase 1 (PLK1), has an oncogenic role in ovarian cancer. Gain and loss of function assays on mouse models and ex vivo patient-derived ascites cultures revealed an oncogenic role of BORA in tumor development and a transcriptome-analysis in clinically representative models depicted BORA's role in survival, dissemination and inflammatory cancer related-pathways. Importantly, combinatory treatments of FDA-approved inhibitors against oncogenic downstream effectors of BORA displayed synergistic effect in ovarian cancer models, offering promising therapeutic value. Altogether, our findings uncovered for the first time a critical role of BORA in the viability of human cancer cells providing potential novel therapeutic opportunities for ovarian cancer management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic Biomarkers in Endometrial Cancer, A Systematic Review and Meta-Analysis

  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Martinez-Garcia, Elena|||0000-0003-2547-7916
  • Dittmar, Gunnar|||0000-0003-3647-8623
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and its mortality is directly associated with the presence of poor prognostic factors driving tumor recurrence. Stratification systems are based on few molecular, and mostly clinical and pathological parameters, but these systems remain inaccurate. Therefore, identifying prognostic EC biomarkers is crucial for improving risk assessment pre- and postoperatively and to guide treatment decisions. This systematic review gathers all protein biomarkers associated with clinical prognostic factors of EC, recurrence and survival. Relevant studies were identified by searching the PubMed database from 1991 to February 2020. A total number of 398 studies matched our criteria, which compiled 255 proteins associated with the prognosis of EC. MUC16, ESR1, PGR, TP53, WFDC2, MKI67, ERBB2, L1CAM, CDH1, PTEN and MMR proteins are the most validated biomarkers. On the basis of our meta-analysis ESR1, TP53 and WFDC2 showed potential usefulness for predicting overall survival in EC. Limitations of the published studies in terms of appropriate study design, lack of high-throughput measurements, and statistical deficiencies are highlighted, and new approaches and perspectives for the identification and validation of clinically valuable EC prognostic biomarkers are discussed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer

  • Megino-Luque, Cristina
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Molins-Escuder, Clara|||0000-0003-3342-956X
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Eritja, Núria
Patients diagnosed with endometrial cancer (EC), the most common gynaecological malignancy in women worldwide, cope with a disease associated with poor prognosis and limited treatment options after first-line therapy when it reaches an advanced or metastatic stage. Lately, small-molecule inhibitors have emerged as an alternative targeted therapy, renewing hope in the fight against this disease. The aim of this review is to shed light into the current state and future prospects of small-molecule inhibitors on EC treatment by summarizing the extensive number of clinical trials that have been performed during the last years, and to provide a comprehensive up-to-date document with the most remarkable results. Despite the great effort researchers are making to improve the molecular characterization of tumours, to unravel the underlying mechanism of EC progression, and to increase the efficacy of targeted therapy, we might say that there is still a long way to pave to efficiently treat EC patients. Endometrial cancer (EC) is the sixth most common cancer in women. A continued number of low-risk EC patients at diagnosis, as well as patients diagnosed with advanced-stage disease, will experience an aggressive disease. Unfortunately, those patients will present recurrence or overt dissemination. Systemic cytotoxic chemotherapy treatment on advanced, recurrent, or metastatic EC patients has shown poor results, with median survival rates of less than one year, and median progression-free survival rates of four months. Therefore, the search for innovative and alternative drugs or the development of combinatorial therapies involving new targeted drugs and standard regimens is imperative. Over the last few decades, some small-molecule inhibitors have been introduced in the clinics for cancer treatment, but only a few have been approved by the Food and Drug Administration (FDA) for EC treatment. In the present review, we present the current state and future prospects of small-molecule inhibitors on EC treatment, both alone and in combination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

  • Mota, Alba
  • Oltra, Sara S.
  • Selenica, Pier
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Diaz, Eva
  • Gatius, Sonia
  • Ruiz-Miro, María
  • Calvo, Ana|||0000-0002-7953-2629
  • Rojo-Sebastián, Alejandro
  • Hurtado Blanco, P.
  • Piñeiro, Roberto|||0000-0001-9479-139X
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Reis-Filho, Jorge S.|||0000-0003-2969-3173
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Weigelt, Britta|||0000-0001-9927-1270
  • Moreno-Bueno, Gema
Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors' evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cervical Fluids Are a Source of Protein Biomarkers for Early, Non-Invasive Endometrial Cancer Diagnosis

  • Martinez-Garcia, Elena|||0000-0003-2547-7916
  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Lesur, Antoine
  • Dittmar, Gunnar|||0000-0003-3647-8623
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Colás Ortega, Eva|||0000-0003-0302-4828
Abnormal uterine bleeding (AUB) is the main symptom of endometrial cancer (EC), but it is highly nonspecific. This represents a huge burden for women's health, since all women presenting with bleeding will undergo sequential invasive tests, avoidable in 90-95% of those women who do not have EC. This study aimed to evaluate the potential of cervical samples collected with five different devices as a source of EC diagnostic protein biomarkers. Samples collected with a Rovers Cervex Brush ® and the HC2 DNA collection device, Digene, were the most suitable for EC proteomic studies. A clinical retrospective study assessing the expression of 52 EC-related proteins in 41 patients (22 EC; 19 non-EC), by targeted proteomics, identified SERPINH1, VIM, TAGLN, PPIA, CSE1L, and CTNNB1 as potential EC protein biomarkers in cervical fluids (AUC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool

  • Villafranca-Magdalena, Beatriz|||0000-0001-9921-919X
  • Masferrer-Ferragutcasas, Carina|||0000-0002-4561-1820
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Rebull, Marta
  • Parra, Genis
  • García, Ángel
  • Reques, Armando|||0000-0002-7197-9354
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
Endometrial cancer (EC) is the second most frequent gynecological cancer worldwide. Although improvements in EC classification have enabled an accurate establishment of disease prognosis, women with a high-risk or recurrent EC face a dramatic situation due to limited further treatment options. Therefore, new strategies that closely mimic the disease are required to maximize drug development success. Patient-derived xenografts (PDXs) are widely recognized as a physiologically relevant preclinical model. Hence, we propose to molecularly and histologically validate EC PDX models. To reveal the molecular landscape of PDXs generated from 13 EC patients, we performed histological characterization and whole-exome sequencing analysis of tumor samples. We assessed the similarity between PDXs and their corresponding patient's tumor and, additionally, to an extended cohort of EC patients obtained from The Cancer Genome Atlas (TCGA). Finally, we performed functional enrichment analysis to reveal differences in molecular pathway activation in PDX models. We demonstrated that the PDX models had a well-defined and differentiated molecular profile that matched the genomic profile described by the TCGA for each EC subtype. Thus, we validated EC PDX's potential to reliably recapitulate the majority of histologic and molecular EC features. This work highlights the importance of a thorough characterization of preclinical models for the improvement of the success rate of drug-screening assays for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer

  • Coll de la Rubia, Eva|||0000-0001-6709-7554
  • Martinez-Garcia, Elena|||0000-0003-2547-7916
  • Dittmar, Gunnar|||0000-0003-3647-8623
  • Nazarov, Petr V.
  • Bebia, Vicente|||0000-0001-6434-2112
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Colás Ortega, Eva|||0000-0003-0302-4828
Endometrial cancer (EC) mortality is directly associated with the presence of poor prognostic factors. Molecular prognostic factors have been identified, but none are used in clinical practice due to lack of validation studies. This study aims to validate a set of 255 prognostic biomarkers previously identified in an extensive literature review and explore new prognostic applications by analyzing them in The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases. A total of 30 biomarkers were validated and associated to a histological type (n = 15), histological grade (n = 6), FIGO stage (n = 1), molecular classification (n = 16), overall survival (n = 11), and recurrence-free survival (n = 5). Our results encourage further studies of understudied biomarkers such as TPX2, and validates already broadly studied biomarkers such as MSH6, MSH2, or L1CAM, among others. Finally, our results present a significant step to advance the quest for biomarkers to accurately assess the risk of EC patients. Endometrial cancer (EC) mortality is directly associated with the presence of prognostic factors. Current stratification systems are not accurate enough to predict the outcome of patients. Therefore, identifying more accurate prognostic EC biomarkers is crucial. We aimed to validate 255 prognostic biomarkers identified in multiple studies and explore their prognostic application by analyzing them in TCGA and CPTAC datasets. We analyzed the mRNA and proteomic expression data to assess the statistical prognostic performance of the 255 proteins. Significant biomarkers related to overall survival (OS) and recurrence-free survival (RFS) were combined and signatures generated. A total of 30 biomarkers were associated either to one or more of the following prognostic factors: histological type (n = 15), histological grade (n = 6), FIGO stage (n = 1), molecular classification (n = 16), or they were associated to OS (n = 11), and RFS (n = 5). A prognostic signature composed of 11 proteins increased the accuracy to predict OS (AUC = 0.827). The study validates and identifies new potential applications of 30 proteins as prognostic biomarkers and suggests to further study under-studied biomarkers such as TPX2, and confirms already used biomarkers such as MSH6, MSH2, or L1CAM. These results are expected to advance the quest for biomarkers to accurately assess the risk of EC patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Screening Strategies to Improve Early Diagnosis in Endometrial Cancer

  • De la Calle Fuentes, Irene
  • Baulies, Sonia
  • Cabrera, Silvia
  • Gil-Moreno, Antonio
  • Colás Ortega, Eva
Diagnosis; Endometrial cancer; Screening, Diagnòstic; Càncer d'endometri; Cribratge, Diagnóstico; Cáncer de endometrio; Cribado, Endometrial cancer is the most common gynecological malignancy in high-income countries and the sixth most common cancer in women. Overall incidence has risen in the last few decades as a consequence of the increase in the prevalence of its risk factors, mainly obesity and the aging of the population, and although diagnoses have increased across all age groups, the incidence rates have doubled in women under the age of 40 years. The survival rates of endometrial cancer are highly dependent on its stage at diagnosis, bringing to the fore the importance of early diagnosis. The aim of a screening strategy in this type of tumor should be to detect the disease in the pre-invasive or early stage (before developing myometrial invasion), which would improve cure rates, reduce the morbidity associated with aggressive treatment and offer uterus-sparing management options for younger women. The ideal screening tool in this scenario would be a minimally invasive, inexpensive and easy-to-perform test or auto-test, which could be implemented in a routine gynecologic checkup of patients at-risk or in the general adult population. In this comprehensive review, we aim to define the populations at higher risk of developing endometrial cancer, to assess the performance of current diagnostic tools when used in a screening setting and to discuss the accuracy of new molecular screening strategies., This research was funded by: Instituto de Salud Carlos III (ISCIII) grant number PI20/00644, PI23/01470, IFI19/00029 to E.C.R., IFI22/00019 to I.C., and CP22/00147 to E.C.; Grant number AC21_2/00030; Ministerio de Ciencia, Innovación y Universidades through a Proyectos en Colaboración Publico-Privada 2021 grant number CPP2022-009817, co-financed by the European Regional Development Fund (FEDER); Generalitat de Catalunya: SGR 2021 01157; CIBERONC network grant number CB16/12/00328; European Comission by Era PerMed project financed by AECC (grant number PERME212443COLA).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta
  • Gatius, Sònia
  • Bonnin, Sarah
  • Ruiz-Miró, Maria
  • González, Esperanza
  • Gil Moreno, Antonio
  • Colas Ortega, Eva
  • Moiola, Cristian Pablo
Taqman OpenArray technology; Lung cancer diagnosis; Biomarkers, Tecnología Taqman OpenArray; Diagnóstico de cáncer de pulmón; Biomarcadores, Tecnologia Taqman OpenArray; Diagnòstic del càncer de pulmó; Biomarcadors, Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis., The sample collection was supported by IRBLleida BIOBANK (B.0000682) and Plataforma biobancos PT17/0015/0027.EC hold a postdoctoral fellowship from the Departament de Salut of the Generalitat de Catalunya (SLT002/16/00274). This study was supported by: “Discovery, validation and implementation of biomarkers for Precision Oncology” (ISCIII PIE15/00029), CIBERONC (CB16/12/00231 and CB16/12/00328), Grups consolidats de la Generalitat de Catalunya (2017SGR1368 and 2017SGR1661) and Asociación Española contra el Cancer (GCTRA1804MATI).